RP

Sid Meier's Civilization® VII Coming In 2025

Retrieved on: 
Venerdì, Giugno 7, 2024
Electronic Games, Entertainment, TTWO, Multimedia, Firaxis Games, Civilization, Linux, Steam, RP, Take-Two Interactive, History, Mac, ESRB, CIV, Love, Creative, Video game

Available to wishlist now on select platforms, the full reveal of Civilization VII and its exciting new features and innovations will be shared in August 2024.

Key Points: 
  • Available to wishlist now on select platforms, the full reveal of Civilization VII and its exciting new features and innovations will be shared in August 2024.
  • “What the team is looking to accomplish with Civilization VII is nothing short of breathtaking, and we're confident that Firaxis Games has another hit on their hands with Civilization VII."
  • As the seventh mainline title in the franchise, Civilization VII is a 4X strategy game developed by the legendary team at Firaxis Games.
  • Sid Meier's Civilization VII is currently rated RP for Rating Pending by the ESRB.

LambdaVision Announces First Closing of Seed Round to Advance Artificial Retina Preclinical Studies for Retinal Eye Diseases

Retrieved on: 
Mercoledì, Maggio 29, 2024
Science, Biotechnology, Research, Optical, Health, Aerospace, Manufacturing, Clinical Trials, GP, Yale New Haven Hospital, NASA, Bangladesh Technical Education Board, Doctor of Philosophy, Patient, AMD, Hope, National Science Foundation, SBIR, Yale school, Patent, International Space Station, IND, RP, Yale School of Medicine, MIT, NSF, Small Business Innovation Research, NIH, Bacteriorhodopsin, Human, Pharmaceutical industry

LambdaVision , an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund , a fund spun out of MIT.

Key Points: 
  • LambdaVision , an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund , a fund spun out of MIT.
  • The round also includes investment from Boryung, a publicly listed Korean pharmaceutical company, and E2MC Ventures.
  • While the preclinical studies are being conducted on Earth, LambdaVision is optimizing assembly of its artificial retina in low-Earth orbit.
  • “We are proud to lead this seed round with LambdaVision and eager to support bringing a life-changing product to market,” said Ariel Ekblaw, GP, Aurelia Foundry Fund.

Sixteen Ingenious Youth Recognized for Outstanding Innovation

Retrieved on: 
Giovedì, Maggio 9, 2024
Civic, Well, Hypothermia, Award, Agriculture, Humidity, Equity, EVS, Rideau Hall Foundation, Learning, Ice, Weather, RP, AI, AQM, Health, Machine learning, Water, Artificial intelligence, Forecasting, Farmer, Smartphone, Inclusion, Human, Algorithm, Calmos, Climate change, RHF, Static pressure, Environment, GNSS, Community, Student, Temperature, Anxiety, Accident, Entrepreneurship

OTTAWA, ON, May 9, 2024 /PRNewswire/ -- Sixteen outstanding youth from across Canada will be recognized by the Rideau Hall Foundation (RHF) during Canadian Innovation Week (May 13-17) for their problem-solving projects ranging from disability-friendly toys customized by 3D printing to a personalized, portable air quality monitor.

Key Points: 
  • OTTAWA, ON, May 9, 2024 /PRNewswire/ -- Sixteen outstanding youth from across Canada will be recognized by the Rideau Hall Foundation (RHF) during Canadian Innovation Week (May 13-17) for their problem-solving projects ranging from disability-friendly toys customized by 3D printing to a personalized, portable air quality monitor.
  • The honourees, aged 14 to 18, are national winners and finalists of the RHF's Ingenious+ youth innovation challenge , which gives young innovators a chance to advance their ideas through financial support, learning opportunities, and mentorship.
  • "We are thrilled to be honouring this group of youth during Canadian Innovation Week," says Teresa Marques, President and CEO of the RHF.
  • The Ingenious+ 2024 National Awards ceremony will take place in Ottawa on May 15 at 1 p.m.

EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting

Retrieved on: 
Lunedì, Maggio 6, 2024
Clinical trial, RP, EDAP, Trial of the century, Prostate cancer, Patient, AUA, Pharmaceutical industry

Professor Pascal Rischmann of Rangueil University Hospital in Toulouse, France, and lead investigator of the HIFI Study, highlighted the final results from the study during an oral presentation at the AUA plenary session, “Paradigm-shifting, Practice-changing Clinical Trials in Urology”.

Key Points: 
  • Professor Pascal Rischmann of Rangueil University Hospital in Toulouse, France, and lead investigator of the HIFI Study, highlighted the final results from the study during an oral presentation at the AUA plenary session, “Paradigm-shifting, Practice-changing Clinical Trials in Urology”.
  • HIFI is the first prospective, multi-center, investigator-sponsored study comparing robotic HIFU to RP in the management of prostate cancer.
  • The study, which ran from April 2015 through March 2022, compared Focal One HIFU versus RP as a first line treatment for patients with localized prostate cancer (grade groups
  • EDAP remains well positioned to deliver this technology as we continue to build world-class treatment programs for urologists centered around our leading Focal One robotic HIFU technology platform.”

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Retrieved on: 
Lunedì, Maggio 6, 2024
Oncology, Health, Technology, Health Technology, Genetics, Artificial Intelligence, Biotechnology, RUO, University, Prostate, NCCN, RC, International, RP, Risk, Grade, American Urological Association, Survival, Neoadjuvant therapy, PSA, Columbia University, Integration, Research, Pathology, GSC, Prostate cancer, Prostate-specific antigen, University of Michigan, Patient, NOC, Urology, Intelligence, AUA, MRI, Biopsy, Gene expression, Diagnosis, MUSIC, Waiting, Bladder cancer, Radical, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.
  • They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases.
  • Summary: The Decipher Prostate Genomic Classifier is associated with adverse pathology in patients eligible for Active Surveillance (AS) who were treated with radical prostatectomy (RP).
  • Podium Presentation PD42-03 : Understanding Population-Wide Genomic Risk Distribution and Integrating Clinical-Genomic Risk for Prognostication in Prostate Cancer.

Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery

Retrieved on: 
Venerdì, Maggio 3, 2024
BCR, RP, Risk, Johnson & Johnson, Recurrence, ADT, Research, Abstract, Prostate cancer, Disease, Patient, Urology, Neoplasm, Surgical oncology, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months.1 These data were presented today at an Oral Presentation Session (Abstract #P2-07) at the 2024 American Urological Association Annual Meeting AUA, May 3-6, 2024, in San Antonio, Texas. 

Key Points: 
  • SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
  • * "Results from this study encourage additional research for high-risk localized prostate cancer and highlight the promise of bringing treatment into earlier stages of disease following radical prostatectomy."
  • The study met its primary endpoint, showing that patients who received 12 months of ERLEADA® plus ADT adjuvant to RP experienced no confirmed biochemical recurrence after 12 additional months of follow-up.
  • The treatment regimen demonstrated a serum testosterone recovery (≥150 ng/dL) rate of 76.4% at 12 months (95% CI, 65.0–84.5).

Progress Software Corp. Statement regarding a Possible Offer for MariaDB plc

Retrieved on: 
Venerdì, Aprile 19, 2024
Part, RP, AI, Environment, Possibility, Senior, MariaDB, Acquisition, RDBMS, Database

Further to the announcement made by Progress Software Corp. (“Progress”) on March 26, 2024 (the “March Possible Offer Announcement”), Progress is today announcing, under Rule 2.4 of the Irish Takeover Rules, that it is considering a possible offer (the “Possible Offer”) to acquire all of the debt and the entire issued and to be issued share capital of MariaDB plc (“MariaDB”).

Key Points: 
  • Further to the announcement made by Progress Software Corp. (“Progress”) on March 26, 2024 (the “March Possible Offer Announcement”), Progress is today announcing, under Rule 2.4 of the Irish Takeover Rules, that it is considering a possible offer (the “Possible Offer”) to acquire all of the debt and the entire issued and to be issued share capital of MariaDB plc (“MariaDB”).
  • Under the Possible Offer, each MariaDB shareholder would be entitled to receive:
    $0.60 for each MariaDB share, payable in cash.
  • Progress believes that the Possible Offer aligns to Progress’ strategy and track record of acquisitions, and MariaDB meets many aspects of Progress’ disciplined approach to acquisitions.
  • Progress confirms that the Possible Offer is a possible offer under Rule 2.4 of the Irish Takeover Rules for all the issued and to be issued share capital of MariaDB.

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Retrieved on: 
Mercoledì, Aprile 10, 2024
FDA, RP, Retinitis pigmentosa, Safety, Marketing, MAA, CHMP, Vaccine, U.S. FDA, Arm, IND, Patient, EMA, Committee, RHO, BLA, Clinical trial, Leber congenital amaurosis, European Medicines Agency

EMA provided this opinion based on safety and tolerability of OCU400 demonstrated in the Phase 1/2 study.

Key Points: 
  • EMA provided this opinion based on safety and tolerability of OCU400 demonstrated in the Phase 1/2 study.
  • In each arm, participants will be randomized 2:1 to the treatment group (2.5 x 1010 vg/eye of OCU400) and untreated control group, respectively.
  • The positive scientific advice from EMA is in alignment with U.S. FDA clearance of the IND amendment to initiate the Phase 3 liMeliGhT clinical trial of OCU400.
  • OCU400 is the first gene therapy to enter Phase 3 with a broad RP indication.

Science Corporation Acquires Pixium’s PRIMA Retinal Implant, Extending and Diversifying Its Commitment to Vision Restoration Through Brain-Computer Interface Technology

Retrieved on: 
Giovedì, Aprile 25, 2024
Research, Medical Devices, Genetics, Clinical Trials, Health Technology, Biotechnology, Health, Optical, Science, Diamond, Blog, Stanford University, AMD, IP, Cell, Corporation, RP, Retinitis pigmentosa, BCI, Paratriathlon, Trigeminal ganglion, Retina, PRIMA, Patient, Acquisition, Optic nerve, Clinical trial, Medical imaging

Science Corporation (“Science”), a leader in brain-computer interface (“BCI”) technology and the developer of the Science Eye , has acquired the IP and related assets for the PRIMA retinal implant , developed by Pixium Vision SA (“Pixium”) of France, a bioelectronics BCI technology company.

Key Points: 
  • Science Corporation (“Science”), a leader in brain-computer interface (“BCI”) technology and the developer of the Science Eye , has acquired the IP and related assets for the PRIMA retinal implant , developed by Pixium Vision SA (“Pixium”) of France, a bioelectronics BCI technology company.
  • Together with the work being done at Science on the Science Eye, we now have two great opportunities to develop BCI technology for the potential restoration of vision in certain patients with severe vision loss.
  • Pixium’s PRIMA system features a miniaturized, wireless, subretinal implant (originally developed at Stanford University) paired with a pocket computer, and glasses.
  • Science CEO Hodak continued: “Science is now developing advanced innovative products using two very different modalities.

Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor

Retrieved on: 
Giovedì, Aprile 25, 2024
Stargardt disease, RP, State, Stargardt, Research, Diabetic retinopathy, Communication, FACS, Thomas Jefferson University, Patient, Geographic atrophy, American Academy of Ophthalmology, Clinical trial, Therapy, AAO, Medical device

DALLAS, April 25, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical Advisor, where he will help define the strategy of developing the gene mutation-agnostic therapies.

Key Points: 
  • DALLAS, April 25, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc. , a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical Advisor, where he will help define the strategy of developing the gene mutation-agnostic therapies.
  • Dr. Ho is Attending Surgeon and Director of Retina Research at Wills Eye Hospital and Co-Director of the Wills Eye Hospital Retina Service.
  • "We are excited to have Dr. Allen C. Ho join Nanoscope as Chief Medical Advisor," said Sulagna Bhattacharya, Nanoscope co-founder and CEO.
  • "As a world-renowned retina specialist and leader in innovative treatments for retinal diseases, his insight will be invaluable to Nanoscope.